Announced details
50 cases scheduled for data collection and included in the study
The Company has entered into a memorandum of understanding with Fujita Health University, Atransen Pharma株式会社, SUMITOMO HEAVY INDUSTRIES,LTD. and 株式会社フジタ concerning the promotion of BNCT research and development targeting deep-seated tumors, and is participating in the research and development project.
Fujita Health University has a track record in clinical research. SUMITOMO HEAVY INDUSTRIES,LTD. has technology for developing BNCT systems. The location, representative, capital, year of establishment and business description of Atransen Pharma株式会社 and 株式会社フジタ are Not disclosed.
The initiative is positioned as contributing to the future expansion of BNCT indications and business opportunities, but the specific impact on results for the current fiscal year is Not disclosed.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Steboronin®, 18F-FBPA PET, BNCT |
| Counterparty | Fujita Health University, Atransen Pharma株式会社, SUMITOMO HEAVY INDUSTRIES,LTD., 株式会社フジタ |
| Counterparty overview | Fujita Health University has a track record in clinical research. SUMITOMO HEAVY INDUSTRIES,LTD. has technology for developing BNCT systems. The location, representative, capital, year of establishment and business description of Atransen Pharma株式会社 and 株式会社フジタ are Not disclosed. |
| Relationship with the Company | The Company has entered into a memorandum of understanding with Fujita Health University, Atransen Pharma株式会社, SUMITOMO HEAVY INDUSTRIES,LTD. and 株式会社フジタ concerning the promotion of BNCT research and development targeting deep-seated tumors, and is participating in the research and development project. |
| Contract Date | December 2024 (memorandum of understanding among the Company, Fujita Health University, Atransen Pharma株式会社, SUMITOMO HEAVY INDUSTRIES,LTD. and 株式会社フジタ) / January 2026 (agreement between SUMITOMO HEAVY INDUSTRIES,LTD. and Fujita Health University for the introduction of a BNCT treatment system and BNCT dose calculation program) |
| Applicable area | Pancreatic cancer, Hepatocellular carcinoma, Biliary tract cancer, Deep-seated cancers |
| Usage history | 50 cases scheduled for data collection and included in the study |
| Impact on Business Performance | The initiative is positioned as contributing to the future expansion of BNCT indications and business opportunities, but the specific impact on results for the current fiscal year is Not disclosed. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Deep-seated cancers present technical challenges, including neutron penetration depth and effects on normal tissue. The study will assess the tumor accumulation of boron drugs in deep-seated cancers and obtain foundational data for the future expansion of BNCT indications.